News
GILD
168.08
+0.08%
0.13
Weekly Report: what happened at GILD last week (1109-1113)?
Weekly Report · 4h ago
Barclays Reaffirms Their Hold Rating on Gilead Sciences (GILD)
TipRanks · 4h ago
SA Asks: What are the most attractive Big Pharma stocks right now?
Seeking Alpha · 18h ago
Gilead Beat the S&P 500 by More Than 25 Points in the Past Year, but $1,000 From a Decade Ago Is Still Worth Less Than $3,500
24/7 Wall St. · 22h ago
Gilead Sciences (GILD) Wins Bixlenvo Approval With Another FDA Call Due In December
Simply Wall St · 1d ago
Gilead Sciences Earnings Call Signals Broad Growth Momentum
TipRanks · 1d ago
Moderna Inc. Stock Slips 3.4%, Underperforms Peers
Dow Jones · 2d ago
Evercore ISI cuts Legend Biotech to In Line ahead of ‘meaningful headwinds’
TipRanks · 2d ago
Gilead (GILD) Stock May Be 44% Undervalued After Lenacapavir News
Simply Wall St · 3d ago
The Zacks Analyst Blog Highlights Home Depot, Gilead Sciences, TotalEnergies, Key Tronic and iPower
NASDAQ · 3d ago
Moderna Inc. Stock Sheds 7.0%, Underperforms Peers
Dow Jones · 3d ago
Top Research Reports for Home Depot, Gilead & TotalEnergies
NASDAQ · 3d ago
3 Pharmaceutical Stocks That Offer Safety and Growth
NASDAQ · 3d ago
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Cardinal Health (CAH)
TipRanks · 4d ago
Gilead price target raised to $190 from $165 at Argus
TipRanks · 4d ago
Gilead enters collaboration with TelevisaUnivision for Latin GRAMMY Awards
TipRanks · 4d ago
Regeneron Pharmaceuticals Inc. Stock Climbs 4.7%, Outperforms Peers
Dow Jones · 4d ago
Gilead Sciences (GILD) Faces A Valuation Test Following Lenacapavir PrEP Data
Simply Wall St · 5d ago
Compugen: COM701 Data On Track And Continued Bispecific Rilvegostomig Development
Seeking Alpha · 5d ago
Scotiabank Keeps Their Buy Rating on Gilead Sciences (GILD)
TipRanks · 6d ago
More
Webull provides a variety of real-time GILD stock news. You can receive the latest news about Gilead Sciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The Company also owns an antibody-drug conjugates (ADCs) platform.